-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Differentiated thyroid tumors account for about 90% of thyroid cancer cases, and the typical treatment is surgical treatment and then the ablation of the remaining thyroid tissue with radioactive iodine, but about 5% to 15% of cases are resistant to radioactive iodine therapy.
for these patients, life expectancy is only three to six years, starting with the discovery of metastasis lesions.
Cabometyx is a multi-kinase inhibitor that inhibits c-Met, VEGFR2, Axl and Ret.
has been approved by the FDA to treat patients with advanced renal cell carcinoma and 1st-century patients with hepatocellular carcinoma who have previously been treated with sorafenib.
In a critical Phase 3 clinical trial called COSMIC-311, randomized double-blind, placebo-containing control, about 300 patients with radioactive iodine incurable differentiated thyroid cancer were treated with Cabometyx or a placebo.
patients had previously been treated with up to two VEGFR targeted therapies, but the disease continued to progress.
results of the trial will be presented at a future medical conference.
: s1. Exelixis Announces Cabozantinib GreatEry Progression-Free Survival in COSMIC-311 Phase 3 Pivotal Trial in Patients with Previously Treated Radioiodine-Refractory Rogered Thyroid Cancer. Retrieved December 21, 2020, from